Baker Ellis Asset Management LLC Sells 10,445 Shares of Novartis AG (NVS)

Baker Ellis Asset Management LLC lowered its stake in Novartis AG (NYSE:NVS) by 27.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,321 shares of the company’s stock after selling 10,445 shares during the period. Baker Ellis Asset Management LLC’s holdings in Novartis were worth $2,354,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Arbitrage SA lifted its holdings in Novartis by 294.8% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,482 shares of the company’s stock valued at $263,000 after acquiring an additional 2,600 shares during the last quarter. OLD National Bancorp IN lifted its holdings in Novartis by 36.6% in the 2nd quarter. OLD National Bancorp IN now owns 14,723 shares of the company’s stock valued at $1,112,000 after acquiring an additional 3,947 shares during the last quarter. Hedeker Wealth LLC acquired a new stake in Novartis in the 2nd quarter valued at about $365,000. Eqis Capital Management Inc. lifted its holdings in Novartis by 8.4% in the 2nd quarter. Eqis Capital Management Inc. now owns 20,327 shares of the company’s stock valued at $1,535,000 after acquiring an additional 1,577 shares during the last quarter. Finally, Telos Capital Management Inc. lifted its holdings in Novartis by 2.2% in the 2nd quarter. Telos Capital Management Inc. now owns 37,130 shares of the company’s stock valued at $2,805,000 after acquiring an additional 787 shares during the last quarter. Institutional investors own 10.99% of the company’s stock.

NVS stock opened at $88.03 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.20 and a debt-to-equity ratio of 0.29. Novartis AG has a one year low of $72.30 and a one year high of $94.19. The stock has a market cap of $206.32 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 1.97 and a beta of 0.73.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Thursday, October 18th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.01. Novartis had a net margin of 25.98% and a return on equity of 15.81%. The company had revenue of $12.78 billion during the quarter, compared to analyst estimates of $12.88 billion. During the same period in the prior year, the firm earned $1.29 earnings per share. The business’s quarterly revenue was up 2.9% on a year-over-year basis. Sell-side analysts predict that Novartis AG will post 5.17 EPS for the current year.

A number of brokerages have weighed in on NVS. Goldman Sachs Group raised shares of Novartis from a “neutral” rating to a “conviction-buy” rating in a report on Friday, November 16th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a report on Tuesday, November 6th. Wolfe Research began coverage on shares of Novartis in a report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Guggenheim began coverage on shares of Novartis in a report on Monday, October 8th. They issued a “neutral” rating for the company. Finally, Zacks Investment Research raised shares of Novartis from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a report on Tuesday, September 18th. Eleven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $84.86.

TRADEMARK VIOLATION WARNING: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/25/baker-ellis-asset-management-llc-sells-10445-shares-of-novartis-ag-nvs.html.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

See Also: Return on Equity (ROE)

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply